Mylet Johanna 4
4 · Poseida Therapeutics, Inc. · Filed Dec 22, 2021
Insider Transaction Report
Form 4
Mylet Johanna
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2021-12-21$1.17/sh+2,616$3,069→ 31,131 total - Exercise/Conversion
Common Stock
2021-12-21$1.93/sh+3,100$5,992→ 34,231 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-21−3,100→ 3,816 totalExercise: $1.93Exp: 2028-02-05→ Common Stock (3,100 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-21−2,616→ 0 totalExercise: $1.17Exp: 2026-02-28→ Common Stock (2,616 underlying)
Footnotes (2)
- [F1]The stock option is fully vested and exercisable.
- [F2]12.5% of the shares shares subject to the stock option vested and became exercisable on August 6, 2018, and the remaining shares vest in 42 equal monthly installments thereafter.